Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex

Nature Communications

Volumn 6, Issue , 2015, Pages

  Balasubramani, Anand ^a,b   Larjo, Antti ^c   Bassein, Jed A ^a,b   Chang, Xing ^a,b   Hastie, Ryan B ^a   Togher, Susan M ^a   Lähdesmäki, Harri ^c   Rao, Anjana ^a,b,d,e  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b SANFORD CONSORTIUM FOR REGENERATIVE MEDICINE   (United States)

^c AALTO UNIVERSITY   (Finland)

^d San Diego   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 ASSOCIATED PROTEIN 1; HISTONE H2A; HISTONE H3; PROTEIN; UNCLASSIFIED DRUG; ASXL1 PROTEIN, HUMAN; BAP1 PROTEIN, HUMAN; HISTONE; REPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

CANCER; CATALYSIS; CELL ORGANELLE; GENE EXPRESSION; GENETIC ANALYSIS; MUTATION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASXL1 GENE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE; GENE REPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA; LOSS OF FUNCTION MUTATION; MAST CELL; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PROMOTER REGION; STABLE EXPRESSION; UBIQUITINATION; UPREGULATION; ANIMAL; C57BL MOUSE; CRANIOFACIAL SYNOSTOSIS; CYTOLOGY; GENETICS; HEK293 CELL LINE; INTELLECTUAL IMPAIRMENT; METABOLISM; MUTATION; MYELOID LEUKEMIA;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CRANIOSYNOSTOSES; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HISTONES; HUMANS; INTELLECTUAL DISABILITY; LEUKEMIA, MYELOID; MAST CELLS; MICE; MICE, INBRED C57BL; MUTATION; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 84934945331     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms8307     Document Type: Article

References (64)

1. Jurgens, G. A group of genes controlling expression of the bithorax complex. Nature 316, 1985 (1985).
2. Wang, H. et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873-878 (2004).
3. Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P. & Reinberg, D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16, 2893-2905 (2002).
4. Muller, J. et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111, 197-208 (2002).
5. Czermin, B. et al. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 111, 185-196 (2002).
6. Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039-1043 (2002).
7. Bracken, A. P. & Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9, 773-784 (2009).
8. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
9. Levine, S. S. et al. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol. Cell. Biol. 22, 6070-6078 (2002).
10. Schoeftner, S. et al. Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J. 25, 3110-3122 (2006).
11. Tavares, L. et al. RYBP-PRC1 complexes mediate H2A ubiquitylation at polycomb target sites independently of PRC2 and H3K27me3. Cell 148, 664-678 (2012).
12. Gao, Z. et al. PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol. Cell 45, 344-356 (2012).
13. Blackledge, N. P. et al. Variant PRC1 complex-dependent H2A ubiquitylation drives PRC2 recruitment and Polycomb domain formation. Cell 157, 1445-1459 (2014).
14. Kalb, R. et al. Histone H2A monoubiquitination promotes histone H3 methylation in Polycomb repression. Nat. Struct. Mol. Biol. 21, 569-571 (2014).
15. Scheuermann, J. C. et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 465, 243-247 (2010).
16. Katoh, M. Functional and cancer genomics of ASXL family members. Br. J. Cancer 109, 299-306 (2013).
17. Aumann, S. & Abdel-Wahab, O. Somatic alterations and dysregulation of epigenetic modifiers in cancers. Biochem. Biophys. Res. Commun. 455, 24-34 (2014).
18. Huang, Y. & Rao, A. Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet. 30, 464-474 (2014).
19. Dey, A. et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337, 1541-1546 (2012).
20. Huether, R. et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat. Commun. 5, 3630 (2014).
21. Hoischen, A. et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat. Genet. 43, 729-731 (2011).
22. Magini, P. et al. Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations. Am. J. Med. Genet. A 158A, 917-921 (2012).
23. Bainbridge, M. N. et al. De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. Genome Med. 5, 11 (2013).
24. Cimmino, L., Abdel-Wahab, O., Levine, R. L. & Aifantis, I. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 9, 193-204 (2011).
25. Ko, M. & Rao, A. TET2: epigenetic safeguard for HSC. Blood 118, 4501-4503 (2011).
26. Abdel-Wahab, O. et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22, 180-193 (2012).
27. Inoue, D. et al. Myelodysplastic syndromes are induced by histone methylationaltering ASXL1 mutations. J. Clin. Invest. 123, 4627-4640 (2013).
28. Aravind, L. & Iyer, L. M. The HARE-HTH and associated domains: novel modules in the coordination of epigenetic DNA and protein modifications. Cell Cycle 11, 119-131 (2012).
29. Sanchez-Pulido, L., Kong, L. & Ponting, C. P. A common ancestry for BAP1 and Uch37 regulators. Bioinformatics 28, 1953-1956 (2012).
30. Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413 (2010).
31. Bott, M. et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat. Genet. 43, 668-672 (2011).
32. Testa, J. R. et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat. Genet. 43, 1022-1025 (2011).
33. Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 39, D945-D950 (2011).
34. Farcas, A. M. et al. KDM2B links the Polycomb repressive complex 1 (PRC1) to recognition of CpG islands. eLife 1, e00205 (2012).
35. Tsai, S., Bartelmez, S., Sitnicka, E. & Collins, S. Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev. 8, 2831-2841 (1994).
36. Sakata-Yanagimoto, M. et al. Coordinated regulation of transcription factors through Notch2 is an important mediator of mast cell fate. Proc. Natl Acad. Sci. USA 105, 7839-7844 (2008).
37. Kallin, E. M. et al. Genome-wide uH2A localization analysis highlights Bmi1-dependent deposition of the mark at repressed genes. PLoS Genet. 5, e1000506 (2009).
38. Endoh, M. et al. Histone H2A mono-ubiquitination is a crucial step to mediate PRC1-dependent repression of developmental genes to maintain ES cell identity. PLoS Genet. 8, e1002774 (2012).
39. Scheuermann, J. C., Gutierrez, L. & Muller, J. Histone H2A monoubiquitination and Polycomb repression: the missing pieces of the puzzle. Fly (Austin, TX). 6, 162-168 (2012).
40. Heintzman, N. D. et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311-318 (2007).
41. Mikkelsen, T. S. et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 448, 553-560 (2007).
42. Young, M. D. et al. ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic Acids Res. 39, 7415-7427 (2011).
43. Stock, J. K. et al. Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nat. Cell Biol. 9, 1428-1435 (2007).
44. Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315-326 (2006).
45. Traina, F. et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One 7, e43090 (2012).
46. Bejar, R. et al. Clinical effect of point mutations in myelodysplastic syndromes. N. Engl. J. Med. 364, 2496-2506 (2011).
47. Bejar, R. et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 30, 3376-3382 (2012).
48. Ko, M. et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc. Natl Acad. Sci. USA 108, 14566-14571 (2011).
49. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20, 11-24 (2011).
50. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20, 25-38 (2011).
51. Schwartz, Y. B. & Pirrotta, V. A new world of Polycombs: unexpected partnerships and emerging functions. Nat. Rev. Genet. 14, 853-864 (2013).
52. Eskeland, R. et al. Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol. Cell 38, 452-464 (2010).
53. Yu, H. et al. The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Mol. Cell. Biol. 30, 5071-5085 (2010).
54. Wang, J. et al. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 123, 541-553 (2014).
55. Cooper, S. et al. Targeting polycomb to pericentric heterochromatin in embryonic stem cells reveals a role for H2AK119u1 in PRC2 recruitment. Cell Rep. 7, 1456-1470 (2014).
56. Abdel-Wahab, O. et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J. Exp. Med. 210, 2641-2659 (2013).
57. Gaytan de Ayala Alonso, A. et al. A genetic screen identifies novel polycomb group genes in Drosophila. Genetics 176, 2099-2108 (2007).
58. Gutierrez, L. et al. The role of the histone H2A ubiquitinase Sce in Polycomb repression. Development 139, 117-127 (2012).
59. Morita, S., Kojima, T. & Kitamura, T. Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063-1066 (2000).
60. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
61. Zang, C. et al. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics 25, 1952-1958 (2009).
62. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
63. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
64. Roberts, A. & Pachter, L. Streaming fragment assignment for real-time analysis of sequencing experiments. Nat. Methods 10, 71-73 (2013).